A Phase III Randomized Clinical Trial to Evaluate the Safety and Efficacy of an Etoricoxib and Tizanidine Fixed Dose Combination in Subjects With Moderate to Severe Acute Low Back Pain
Latest Information Update: 12 May 2022
At a glance
- Drugs Etoricoxib/tizanidine (Primary) ; Meloxicam; Methocarbamol; Paracetamol
- Indications Back pain
- Focus Adverse reactions; Registrational
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 26 Apr 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 17 Nov 2013 New trial record